Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27911750 | 0.98 | KDM4E (0.47) | KDM4EMEN1KMT2A | |
| SCHEMBL4977764 | 0.89 | PDE3B (0.44) | KDM4E | |
| SCHEMBL14701713 | 0.85 | PTGS2 (0.42) | KDM4E | |
| SCHEMBL30582312 | 0.85 | MAP4K4 (0.43) | KDM4E | |
| SCHEMBL69486 | 0.84 | KDM4E (0.55) | KDM4E | |
| SCHEMBL4423411 | 0.83 | KDM4E (0.55) | KDM4E | |
| SCHEMBL27433676 | 0.83 | KDM4E (0.48) | KDM4E | |
| SCHEMBL4424566 | 0.83 | NPC1 (0.53) | KDM4E | |
| SCHEMBL4425081 | 0.83 | MAP4K4 (0.51) | KDM4E | |
| SCHEMBL27894425 | 0.82 | KDM4E (0.54) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0282502-B1 | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-05-15 | — | — | EP | claimed |
| US-4952698-A | Imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | claimed |
| EP-0282502-A1 | IMIDAZOLE DERIVATIVES. | SCHERING AG (DE) | 1988-09-21 | — | — | EP | claimed |
| WO-1988001268-A1 | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1988-02-25 | — | — | WO | claimed |
| CN-119912433-A | Quinazoline compound containing urea structure and application thereof | 江西科技师范大学 | 2025-05-02 | — | — | CN | disclosed |
| EP-3263583-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | Pharmascience Inc. (CA) | 2018-01-03 | — | — | EP | disclosed |
| EP-2534170-B1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2285783-B1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8481548-B2 | 2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-4-trifluoromethyl-pyrimidine; metabotropic glutamate (mGluR5) receptor antagonist; analgesic, neurodegenerative diseases; psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders, memory deficits, chronic and acute pain | HOFFMAN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| EP-0282502-B1 | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-05-15 | — | — | EP | disclosed |
| US-4952698-A | Imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
| EP-0282502-A1 | IMIDAZOLE DERIVATIVES. | SCHERING AG (DE) | 1988-09-21 | — | — | EP | disclosed |
| WO-1988001268-A1 | IMIDAZOLE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1988-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | KDM4E 1482/4885MEN1 3495/4885KMT2A 843/4885 |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | KDM4E 4537/4885MEN1 3222/4885KMT2A 4596/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | KDM4E 2025/4885MEN1 2766/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.